Tagged Articles

Bayer 274 articles

J&J spent $28.4M for docs to promote blood thinner Xarelto


Johnson & Johnson spent a whopping $28.4 million in 2015 for fees, meals, travel, gifts and royalties – but not research – to health care providers for promotional speeches or consultation involving its top selling anticoagulant Xarelto, according to Propublicae’s updated Dollars for Docs database. It was the highest amount paid by a drug company in 2015 for so-called “general payments” to doctors to promote their meds. Pfizer and Bristol-Myers Squibb’s similar blood thinner, Eliquis, is poised to steal Xarelto’s large share of the blood thinner market. Its makers shelled out $18.8 million in general payments to doctors to help ... Read More

Blood thinner Xarelto ranks as one of the most dangerous drugs according to data report


The blood thinner Xarelto is the 24th most dangerous drug on the market today, according to an analysis by HealthGrove, a health site that uses Graphiq’s semantic technology to deliver deep insights into health practices via data-driven articles, visualizations and research tools. Xarelto, known chemically as rivaroxaban, is made by Johnson & Johnson’s Janssen Pharmaceuticals and Bayer. It was approved by the Food and Drug Administration (FDA) in 2011 and has become the most prescribed blood thinner in its class. Xarelto was designed to be a more convenient alternative to the long-used warfarin for the prevention of strokes in patients ... Read More

Man sues J&J over life threatening side effects allegedly caused by Xarelto


Albert Fields is suing pharmaceutical and consumer healthcare giant Johnson & Johnson alleging the company’s blockbuster blood thinner Xarelto caused him to suffer life-threatening side effects that he was not adequately warned he could suffer. Fields filed his lawsuit against Johnson & Johnson, Janssen Pharmaceuticals, Bayer Healthcare, and their related companies in St. Clair (Illinois) County Circuit Court. According to the claim, the drug companies created the anticoagulant Xarelto and praised it so highly that the Food and Drug Administration (FDA) took issue, calling the ads false and misleading. Xarelto was approved by the FDA in 2011 as the second ... Read More

Pradaxa antidote proves effective; Still no reversal agent for Xarelto


Praxbind, a reversal agent known chemically as idarucizumab, designed to stop the bleeding effects of the blood thinner Pradaxa, worked almost immediately after being administered to patients who developed severe bleeding or needed emergency surgery, with an effect lasting two days, according to a new “real world” clinical analysis of 500 patients. The patients achieved hemostasis within about four hours after administration of the antidote. Most patients went back on Pradaxa after treatment. “When you give idarucizumab, literally within seconds you see reversal. It’s almost instantaneous,” Dr. Charles V. Pollack, with Thomas Jefferson University, Philadelphia, Penn., and principal investigator of the ... Read More

Another Xarelto lawsuit filed in Cook County, Illinois


Lawsuits alleging the blood thinner Xarelto causes serious and life threatening injuries are piling up against the makers of the anticoagulant. One of the latest lawsuits filed is that of Shirley A. Griffin, who filed her complaint in Cook County Circuit Court against Johnson & Johnson, Janssen Pharmaceuticals, Bayer, and their related companies, alleging they failed to warn the public about potential harmful side effects of their blockbuster blood thinner Xarelto. According to the complaint, Griffin suffered severe injuries after taking Xarelto. The medication is used to prevent strokes in patients with the heart rhythm abnormality atrial fibrillation, to prevent ... Read More

Experts explain why Xarelto lawsuit pool is growing in Philadelphia


The federal multidistrict litigation (MDL) involving injuries from the blood thinner Xarelto is holding steady with more than 10,000 cases, but the Xarelto lawsuits consolidated in Philadelphia Court of Common Pleas is growing, according to legal experts with Mass Tort Nexus. The experts say that more lawsuits are being filed in Philadelphia due to two factors – the master complaint was amended to allow for ischemic stroke claims as well as bleeding injury claims, and concerns that a “total lack of diversity” existed during bellwether selection process for the federal Xarelto multidistrict litigation. Judge Arnold New is overseeing the Xarelto lawsuits ... Read More

Judge New sets dates for next six Xarelto lawsuits


The first four cases to serve as bellwether trials in a multidistrict litigation (MDL) involving claims that the blockbuster blood thinner Xarelto caused patients to suffer spontaneous major bleeding events will begin in February 2017. Judge Arnold L. New with the Philadelphia Court of Common Pleas has set six more bellwether trials for next year and organized 24 of the cases for a Core Discovery Pool. The additional six cases are scheduled for Sept. 29, 2017, through Dec. 11, 2017, and alternate between plaintiff picks and defense picks. After the first six cases, the remaining four will be randomly selected. The ... Read More

Boxed warning, patient checklist to come with Essure permanent birth control


The controversial permanent birth control device Essure will now come with an updated safety label that includes a boxed warning about potential injuries and a patient decision checklist to ensure that women who are considering being implanted with the device are aware of the potential risks associated with it. Essure, manufactured by Bayer, was approved by the Food and Drug Administration (FDA) in 2002. It consists of two nickel alloy coils that are inserted into each of the fallopian tubes. Scar tissue builds up around the coils forming a permanent barrier preventing sperm from reaching the egg. In recent years, ... Read More

Xarelto lawsuits alleging stroke risk divided into two categories


People treated with the blood thinner Xarelto who have suffered strokes have filed lawsuits against the manufacturers of the drug alleging they were not adequately warned of the risks associated with the anticoagulant. But the lawsuits claiming stroke risk with Xarelto are divided into two distinct categories and thus two separate multidistrict litigations (MDLs). Xarelto, manufactured by Johnson & Johnson, Janssen Pharmaceuticals and Bayer, is used to prevent strokes caused by blood clots in patients with the heart rhythm abnormality called atrial fibrillation. The medication is also used to treat or prevent deep vein thrombosis and pulmonary embolism, and to ... Read More

Judge Fallon updates Xarelto bellwether schedule


U.S. District Judge Eldon E. Fallon has updated when the first four Xarelto lawsuits – considered bellwethers – will be tried. He postponed the initial bellwether trials, scheduled for Sept. 21, because of the NBA All-Star game and other related logistical issues. The lawsuits claim that Johnson & Johnson, Janssen Pharmaceuticals, Bayer and their related companies did not adequately warn of bleeding risks associated with their blockbuster blood thinner Xarelto. The medication is used to prevent strokes in patients with the heart rhythm abnormality atrial fibrillation, to prevent or treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients ... Read More